Mode
Text Size
Log in / Sign up
N/A N=58 Basic Science

Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT

Erythema · Sensitisation

Enrolled (actual)
58
Serious AEs
0.0%
Results posted
May 2023
Primary outcome: Primary: Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix — 53; 49; 0; 4 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Test Article (Device); Negative Control (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Omeza, LLC
Primary completion
Jan 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix
53; 49; 0; 4; 0; 0
SECONDARY
Adverse Events Deemed Related to the Test Product or the Study
0; 0

Summary

The primary objective of this study was to assess the sensitization potential of Omeza Collagen Matrix compared to that of a negative control based on a Modified Human Repeat Insult Patch Test.

Eligibility Criteria

Inclusion Criteria

  • Good general health, as assessed by medical history and brief dermal skin examination of the application site (back);
  • Was fully informed of the risks of entering the study and was willing to provide written consent to enter the study;
  • Was willing to follow study rules, which included: no sun exposure (for example; no swimming, sunbathing, or tanning beds), avoided activities that would cause excessive sweating, abstained from use of lotions, creams, or oils on the back area;
  • Was willing to not change current brand of personal care products such as soaps, body washes, laundry detergents, body sprays, body spritzes, etc. while participating on the study;
  • Was willing and able to practice an acceptable measure of contraception (i.e. birth control medication for at least 3 months prior, condom with spermicide or birth control injections,) during the study, if female of childbearing potential. To be considered female of non-childbearing potential, subject must have had a hysterectomy, tubal ligation, or had been post-menopausal for at least 1 year.

Exclusion Criteria

  • Clinically significant skin disease which contraindicated participation, including psoriasis, eczema, atopic dermatitis, and active cancer;
  • Asthma that required medication;
  • Insulin-dependent diabetes;
  • Known immunological disorders such as HIV positive, AIDS and systemic lupus
  • erythematosus;
  • Treatment for any type of cancer within the last six months;
  • Routine use (as defined by using more than 3 days in a week) of any anti-inflammatory drug (e.g., aspirin, ibuprofen, corticosteroids; 81 mg aspirin is acceptable), immunosuppressive drugs, antihistamine medication (steroid nose drops and/or eye drops are acceptable) or over-the-counter pain medication that was ingested in quantities exceeding label instructions;
  • Use of topical drugs at patch site;
  • Pregnancy, lactation, or planning a pregnancy (confirmed by a urine pregnancy test administered to females of childbearing potential);
  • Medical condition which, in the Investigator's judgement, made the subject
  • ineligible or placed the subject at undue risk;
  • Participation in any patch test for irritation or sensitization within the last four weeks;
  • Dermatological aberrations in or around test sites which included sunburn, extremely deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or any other disfiguration of the test site;
  • Confirmed allergy to adhesives, bandages, or ingredients in OmezaTM Collagen Matrix;
  • History of anaphylaxis to matrix ingredients (e.g. fish, palm oil, hemp oil, beeswax).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04510675). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search